For the Quarter Ending September 2025
North America
• In United States, the Vancomycin Hydrochloride Price Index rose quarter-over-quarter in Q3 2025, driven by increasing production costs.
• Vancomycin Hydrochloride production costs increased in Q3 2025, influenced by a 3.0% CPI rise in September 2025.
• Producer Price Index increased 2.6% year-over-year in August 2025, indicating higher input costs for manufacturing.
• Demand outlook was mixed in Q3 2025; US economic growth moderated, but healthcare spending continued upward.
• Retail sales, up 5.42% year-over-year in September 2025, and a 4.3% unemployment rate supported demand.
• Consumer Confidence Index declined to 94.2 in September 2025, signaling potential economic headwinds for demand.
• US chemical industry inventories tightened in Q3 2025 due to accelerated destocking, affecting supply.
• Natural gas feedstock and industrial electricity prices strengthened in September 2025, increasing production expenses.
• US industrial production grew only 0.1% year-over-year in September 2025, suggesting a stagnant manufacturing sector.
Why did the price of Vancomycin Hydrochloride change in September 2025 in North America?
• Production costs rose due to a 3.0% CPI increase in September 2025.
• Natural gas feedstock and industrial electricity prices strengthened in September 2025.
• US chemical industry inventories tightened in Q3 2025, driven by accelerated destocking.
APAC
• In China, Vancomycin Hydrochloride Price Index fell quarter-over-quarter in Q3 2025, influenced by falling factory-gate prices.
• Vancomycin Hydrochloride production costs reduced by a -2.3% year-on-year PPI decline in September 2025.
• Robust pharmaceutical market growth supported Vancomycin Hydrochloride demand, despite -0.3% CPI year-on-year in Q3 2025.
• China's Manufacturing Index was contracting in September 2025, reflecting low consumer confidence at 89.6.
• Elevated global petrochemical oversupply contributed to inventory build-up in China during Q3 2025.
• Strong API exports in Q3 2025 were supported by 6.5% industrial production growth.
• National centralized drug procurement policies in 2025 pressured pharmaceutical manufacturing profitability.
• Stable 3.0% retail sales growth and 5.2% unemployment in September 2025 supported healthcare access.
• Vancomycin Hydrochloride Price Forecast: Downward pressure is expected due to oversupply and procurement policies.
Why did the price of Vancomycin Hydrochloride change in September 2025 in APAC?
• Falling factory-gate prices, indicated by a -2.3% PPI year-on-year in September 2025, reduced production costs.
• Increased competition for bulk commodity APIs and global overcapacity led to downward price pressure in Q3 2025.
• National centralized drug procurement policies in 2025 pressured pharmaceutical manufacturing profitability, influencing pricing.
Europe
• In Germany, Vancomycin Hydrochloride Price Index rose in Q3 2025, driven by increasing production costs.
• Production costs increased in Q3 2025, influenced by 2.4% CPI YoY in September 2025.
• The Manufacturing Index contracted in September 2025, indicating potential supply disruptions.
• Germany's industrial production declined by 1.0% YoY in September 2025, impacting efficiency.
• API costs faced upward pressure in Q3 2025 due to new US tariffs, affecting global pricing.
• Demand remained robust in Q3 2025, supported by persistent antibiotic shortages across the EU.
• Wholesale electricity prices in Germany surged in Q3 2025, contributing to higher utility costs.
• Tightened inventory levels for critical medications persisted during Q3 2025 due to supply vulnerabilities.
• Low unemployment at 3.9% in September 2025 potentially increased labor costs for manufacturers.
• Price forecast suggests continued upward pressure from sustained demand and elevated input costs in Q3 2025.
Why did the price of Vancomycin Hydrochloride change in September 2025 in Europe?
• Production costs increased due to surging German wholesale electricity prices in Q3 2025.
• API costs faced upward pressure in Q3 2025 from new US tariffs on Asian suppliers.
• Persistent antibiotic shortages across the EU sustained robust demand for Vancomycin Hydrochloride in Q3 2025.
For the Quarter Ending June 2023
North America
In the US, a decrease of 6.68 percent is seen in the Vancomycin Prices in May compared to the levels observed in April. The prices decreased due to increased supply, less demand, and weakening of currency. China and India are the two biggest producers of Vancomycin. The two countries increased their production in May to keep up with the increased demand for Vancomycin hydrochloride.
Also, some nations eased their regulations on the export of Vancomycin. These factors have increased the global availability of Vancomycin by allowing producers to export more Vancomycin to the US. Apart from that, the war in Ukraine and the rise in inflation subsequently led to decreased demand for Vancomycin hydrochloride in the market.
However, an increment of 1.98% is observed in June from May due to surging demand from end consumers. Aside from that, PMI (Price Manager Index) decremented in June contrasted with earlier months coupled with more demand resulting in the rise of Vancomycin prices in the US market.
Asia Pacific
The prices of Vancomycin decreased by 6.80 percent in May compared to the levels noticed in the previous month. The factors responsible for this downward trend include more supply, decreased demand, and currency fluctuation. The supply of Vancomycin increased due to the lowering cost of raw materials required in making the Vancomycin API that put downward pressure on Vancomycin prices. China’s PMI (Purchasing Manager Index) increased to 50.9 in May from 49.5 in April, demonstrating expansion of China’s industrial activity coupled with limited demand led to a fall in the Vancomycin prices. Aside from this, the Chinese Yuan strengthened against the US dollar, which made Vancomycin expensive for consumers in other countries resulting in a further decrease in demand for Vancomycin API. This is because Vancomycin is priced in US dollars, so when the yuan is strong, it requires more yuan to purchase the same amount of Vancomycin. However, an increment of 1.93% has noticed in June due to a rise in demand from end consumers along with better trade activity.
Europe
In Germany, a downward trend of 6.72 percent is seen in May from the previous month in the second quarter. The factors supporting this downward trend include weak purchasing momentum and overflowing stocks. The supply of Vancomycin rose due to increased manufacturing output and more exports of Vancomycin from foreign countries. Apart from that, the German government eased some of the protocols on the imports of generic medicines and increased the availability of generic Vancomycin, leading to a further decrease in Vancomycin prices. Also, the PMI (Pricing Manager Index) decreased to 42.9 in May from 44.5 in April, indicating a slowing down of the German economy. The economy of Germany is impacted by the war in Ukraine that increased inflation by 7.9% in May, resulting in high food and energy prices. This led to an increase in the cost of living that decreased the demand for Vancomycin. In June 2023, an increment of 1.92 percent was noticed as the demand for Vancomycin surged from end-user sectors.
For the Quarter Ending March 2023
North America
The Vancomycin Hcl displayed steady market dynamics with minimal variation in the first quarter of 2023. As Q1 2023 got underway, prices increased through the end of February, supported by continuous purchases from the pharmaceutical end-user sector. Also, the ease of trade disruption supported the Vancomycin Hcl market trend from January. Furthermore, by the end of Q1 2023, prices had decreased because there were few inquiries and sufficient supplies among the merchants. Low freight costs also contributed to the market's current state of weakness. At the termination of Q1 2023, the settlement price of Vancomycin Hcl API accessed at USD 628105/MT FOB Shanghai with an average quarterly inclination of 0.13%.
Asia Pacific
Vancomycin Hcl prices witnessed a stable upward trajectory in the APAC region in the first quarter of 2023. After the Lunar New Year break, the Chinese pharmaceutical markets technically returned on a positive note with an increase in orders and shipments from both the domestic and the international market. As the market was reopened, factory and port operations resumed. The prices stabilized as the strict Covid laws lifted, revitalizing the second-largest economy in the world. Also, the recovery of production quickened, along with the feeble demand kept the market weak. At the termination of Q1 2023, the settlement price of Vancomycin Hcl API accessed at USD 617455/MT FOB Shanghai with an average quarterly inclination of 0.60%.
Europe
In the first quarter of 2023, Vancomycin Hcl showcased fluctuating market dynamics. With the commencement of Q1 2023, the prices rose till the end of February, backed by consistent offtakes from the pharmaceutical end-user sector. Further, the ease in trade disruption reinforced January's market trend of Vancomycin Hcl. Also, the Euro currency apprenticed against the USD in the month of January, influencing the market sentiments. During the month of March, the settlement price of Vancomycin Hcl API came down to USD 625580/MT CFR Hamburg from USD 660840/MT, with an average quarterly declination of 1.62%. Moreover, by the termination of Q1 2023, the prices dropped as the inquiries remained feeble and the merchants had enough supplies among them. Also, low freight charges further supported the weak market situation.
For the Quarter Ending December 2022
North America
In the fourth quarter of 2022, the price of Vancomycin Hydrochloride increased from $718525/mt to $730650/mt in October and November before falling to $705755/mt in December. China's Golden Week during the first week of October prevented the importation of Vancomycin Hydrochloride from that nation. Due to their huge inventories, domestic suppliers were able to meet the total demand during most part of the quarter, and also, offtakes in the end-user industries remained above average. The second part of the quarter saw a shifting pattern in the market for Vancomycin Hydrochloride because of the sudden rise of Covid cases in China. The supply chain did, however, gradually improve in the second half as the economy expanded, and there was a considerable drop in ship traffic at the ports.
Asia Pacific
Vancomycin Hydrochloride prices in China showed a decreasing price trend during the fourth quarter of 2022 in the Asia Pacific region, with FOB Shanghai values falling from $647455/mt to $606455/mt from October to December. The orders for China's API sector producing Vancomycin Hydrochloride declined steadily during the first week of October as a result of the shutdown of industrial facilities for the Golden Week. It was challenging for the market to catch up to the small rise seen in some downstream industries during the first part of Q4 because Chinese traders had to deal with a range of contradicting signals after a one-week break. However, positive demand kept the market afloat. Large inventory allowed domestic producers and suppliers to meet the total demand for the whole quarter. In reaction to criticism and severe turmoil in the country, the administration revised its zero-covid policies, making the country vulnerable yet again.
Europe
Vancomycin Hydrochloride costs decreased in Europe in the fourth quarter of 2022, with CFR Hamburg values falling from $735110/mt to $720405/mt between October and December. Demand from the overseas market was stronger during the first half of the quarter than it was in December due to the unexpected increase in covid cases, which caused a gradual decline in demand. Domestic demand for Vancomycin Hydrochloride in Germany remained strong during the quarter despite rising energy and raw material costs.
